COX-2 activation has been reported to be involved in the pathogenesis of different hepatic diseases, ranging from non-alcoholic fatty liver disease (NAFLD) to hepatocellular carcinoma. Here, PTGS2 is linked to metabolic dysfunction-associated steatotic liver disease.